clinical trial · NCT05631938
Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose
Achieve Life Sciences·phase1·completed·n = 44
Renal Impairmentcytisinicline
brief summary
The primary objectives of this study are: 1. To obtain information on the pharmacokinetics of cytisinicline following a single oral dose in subjects with varying degrees of renal impairment relative to matched controls with normal renal function. 2. To investigate the extent of cytisinicline removal by hemodialysis.
started
Jan 10, 2023
primary completion
Sep 4, 2023
completion
Sep 4, 2023
last updated
Jul 11, 2025
official title
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol